HEADER MEMBRANE PROTEIN 03-OCT-19 6UJU TITLE STRUCTURE OF THE HIV-1 GP41 TRANSMEMBRANE DOMAIN AND CYTOPLASMIC TAIL TITLE 2 (LLP2) COMPND MOL_ID: 1; COMPND 2 MOLECULE: ENVELOPE GLYCOPROTEIN GP41; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: ENV POLYPROTEIN; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 STRAIN: ISOLATE 92UG024.2; SOURCE 5 GENE: ENV; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PMM-LR6 KEYWDS VIRAL PROTEIN, TRANSMEMBRANE DOMAIN, CYTOPLASMIC TAIL, LIPID BILAYER, KEYWDS 2 MEMBRANE PROTEIN EXPDTA SOLUTION NMR NUMMDL 15 AUTHOR A.PIAI,Q.FU,Y.CAI,F.GHANTOUS,T.XIAO,M.M.SHAIK,H.PENG,S.RITS-VOLLOCH, AUTHOR 2 Z.LIU,W.CHEN,M.S.SEAMAN,B.CHEN,J.J.CHOU REVDAT 3 14-JUN-23 6UJU 1 REMARK REVDAT 2 20-MAY-20 6UJU 1 JRNL REVDAT 1 13-MAY-20 6UJU 0 JRNL AUTH A.PIAI,Q.FU,Y.CAI,F.GHANTOUS,T.XIAO,M.M.SHAIK,H.PENG, JRNL AUTH 2 S.RITS-VOLLOCH,W.CHEN,M.S.SEAMAN,B.CHEN,J.J.CHOU JRNL TITL STRUCTURAL BASIS OF TRANSMEMBRANE COUPLING OF THE HIV-1 JRNL TITL 2 ENVELOPE GLYCOPROTEIN. JRNL REF NAT COMMUN V. 11 2317 2020 JRNL REFN ESSN 2041-1723 JRNL PMID 32385256 JRNL DOI 10.1038/S41467-020-16165-0 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR NIH REMARK 3 AUTHORS : SCHWIETERS, KUSZEWSKI, TJANDRA AND CLORE REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6UJU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 04-OCT-19. REMARK 100 THE DEPOSITION ID IS D_1000244712. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 308 REMARK 210 PH : 6.7 REMARK 210 IONIC STRENGTH : 0 REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : 0.7 MM [U-13C; U-15N; U-85% 2H] REMARK 210 HIV-1 GP41 TMD-CT(LLP2), 40 MM REMARK 210 MES, 40 MM DMPC, 80 MM DHPC, 90% REMARK 210 H2O/10% D2O; 0.8 MM [U-15N; U-2H] REMARK 210 HIV-1 GP41 TMD-CT(LLP2), 40 MM REMARK 210 MES, 40 MM DMPC, 80 MM DHPC, 90% REMARK 210 H2O/10% D2O; 1.0 MM [U-13C; U- REMARK 210 15N] HIV-1 GP41 TMD-CT(LLP2), 40 REMARK 210 MM MES, 40 MM DMPC, 80 MM DHPC, REMARK 210 90% H2O/10% D2O; 0.5 MM [U-15N; REMARK 210 U-2H] HIV-1 GP41 TMD-CT(LLP2), REMARK 210 40 MM MES, 40 MM DMPC, 80 MM REMARK 210 DHPC, 90% H2O/10% D2O; 0.5 MM [U- REMARK 210 15N; U-2H] HIV-1 GP41 TMD-CT REMARK 210 (LLP2), 0.5 MM [U-13C] HIV-1 REMARK 210 GP41 TMD-CT(LLP2), 40 MM MES, 40 REMARK 210 MM DMPC, 80 MM DHPC, 90% H2O/10% REMARK 210 D2O; 0.5 MM [U-15N; U-85% 2H] REMARK 210 HIV-1 GP41 TMD-CT(LLP2), 40 MM REMARK 210 MES, 40 MM DMPC, 80 MM DHPC, 90% REMARK 210 H2O/10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-15N TROSY-HSQC; 3D TROSY REMARK 210 HNCO; 3D TROSY HNCA; 3D TROSY REMARK 210 HN(CA)CO; 3D TROSY HN(CO)CA; 3D REMARK 210 TROSY HNCACB; 3D 15N-EDITED REMARK 210 NOESY-TROSY-HSQC; 2D 1H-13C HSQC; REMARK 210 3D 13C-EDITED NOESY; 3D J(CH)- REMARK 210 MODULATED NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ; 750 MHZ; 800 MHZ; 900 REMARK 210 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE III HD REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : TOPSPIN, NMRPIPE, CARA, XEASY, X REMARK 210 -PLOR NIH REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 150 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 15 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 MODELS 1-15 REMARK 465 RES C SSSEQI REMARK 465 PHE A 717 REMARK 465 GLN A 718 REMARK 465 THR A 719 REMARK 465 HIS A 720 REMARK 465 LEU A 721 REMARK 465 PRO A 722 REMARK 465 THR A 723 REMARK 465 PRO A 724 REMARK 465 ARG A 725 REMARK 465 GLY A 726 REMARK 465 PRO A 727 REMARK 465 ASP A 728 REMARK 465 ARG A 729 REMARK 465 PRO A 730 REMARK 465 GLU A 731 REMARK 465 GLY A 732 REMARK 465 ILE A 733 REMARK 465 GLU A 734 REMARK 465 GLU A 735 REMARK 465 GLU A 736 REMARK 465 GLY A 737 REMARK 465 GLY A 738 REMARK 465 PHE B 717 REMARK 465 GLN B 718 REMARK 465 THR B 719 REMARK 465 HIS B 720 REMARK 465 LEU B 721 REMARK 465 PRO B 722 REMARK 465 THR B 723 REMARK 465 PRO B 724 REMARK 465 ARG B 725 REMARK 465 GLY B 726 REMARK 465 PRO B 727 REMARK 465 ASP B 728 REMARK 465 ARG B 729 REMARK 465 PRO B 730 REMARK 465 GLU B 731 REMARK 465 GLY B 732 REMARK 465 ILE B 733 REMARK 465 GLU B 734 REMARK 465 GLU B 735 REMARK 465 GLU B 736 REMARK 465 GLY B 737 REMARK 465 GLY B 738 REMARK 465 PHE C 717 REMARK 465 GLN C 718 REMARK 465 THR C 719 REMARK 465 HIS C 720 REMARK 465 LEU C 721 REMARK 465 PRO C 722 REMARK 465 THR C 723 REMARK 465 PRO C 724 REMARK 465 ARG C 725 REMARK 465 GLY C 726 REMARK 465 PRO C 727 REMARK 465 ASP C 728 REMARK 465 ARG C 729 REMARK 465 PRO C 730 REMARK 465 GLU C 731 REMARK 465 GLY C 732 REMARK 465 ILE C 733 REMARK 465 GLU C 734 REMARK 465 GLU C 735 REMARK 465 GLU C 736 REMARK 465 GLY C 737 REMARK 465 GLY C 738 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 TRP A 678 162.25 63.55 REMARK 500 1 TYR A 712 -157.69 177.17 REMARK 500 1 PRO A 714 84.49 -7.57 REMARK 500 1 ASP A 741 -5.79 -54.64 REMARK 500 1 LEU A 765 104.05 74.60 REMARK 500 1 PHE A 766 -80.09 79.86 REMARK 500 1 TRP B 678 -85.87 -137.94 REMARK 500 1 PRO B 714 101.49 -34.52 REMARK 500 1 LEU B 715 5.33 -68.83 REMARK 500 1 ASP B 741 -6.75 -57.89 REMARK 500 1 LEU B 765 -58.13 76.12 REMARK 500 1 SER B 767 110.06 59.77 REMARK 500 1 PRO C 714 101.90 -32.06 REMARK 500 1 LEU C 715 8.21 -69.99 REMARK 500 1 ASP C 741 -6.83 -54.85 REMARK 500 1 LEU C 765 -71.99 86.33 REMARK 500 1 PHE C 766 -168.57 -105.18 REMARK 500 1 SER C 767 164.37 -45.47 REMARK 500 1 TYR C 768 88.51 -61.16 REMARK 500 1 HIS C 769 -49.55 -173.02 REMARK 500 2 TYR A 712 -61.42 -171.97 REMARK 500 2 PRO A 714 99.37 -38.05 REMARK 500 2 ASP A 741 -7.09 -54.92 REMARK 500 2 LEU A 765 -26.02 86.63 REMARK 500 2 PHE A 766 -61.79 -138.92 REMARK 500 2 TYR A 768 -179.10 -68.54 REMARK 500 2 HIS A 769 -57.27 77.30 REMARK 500 2 TYR B 712 -53.03 171.24 REMARK 500 2 PRO B 714 93.16 -23.39 REMARK 500 2 ASP B 741 -6.75 -55.65 REMARK 500 2 PHE B 766 -61.91 -176.24 REMARK 500 2 PRO C 714 136.03 -35.31 REMARK 500 2 ASP C 741 -6.40 -56.48 REMARK 500 2 LEU C 765 70.61 64.91 REMARK 500 2 PHE C 766 111.21 59.17 REMARK 500 2 SER C 767 179.95 54.48 REMARK 500 2 TYR C 768 -140.23 -76.03 REMARK 500 2 HIS C 769 -70.48 54.83 REMARK 500 3 TRP A 678 116.96 61.97 REMARK 500 3 TYR A 712 -134.19 48.12 REMARK 500 3 PRO A 714 124.84 -22.44 REMARK 500 3 ASP A 741 -4.94 -53.47 REMARK 500 3 LEU A 765 -51.16 78.44 REMARK 500 3 SER A 767 173.11 56.16 REMARK 500 3 TYR A 768 70.77 -108.12 REMARK 500 3 HIS A 769 -45.00 -155.60 REMARK 500 3 PRO B 714 102.71 -34.83 REMARK 500 3 ASP B 741 -7.03 -55.87 REMARK 500 3 LEU B 765 87.45 77.57 REMARK 500 3 PHE B 766 98.17 62.09 REMARK 500 REMARK 500 THIS ENTRY HAS 299 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5JYN RELATED DB: PDB REMARK 900 5JYN CONTAINS THE TRANSMEMBRANE DOMAIN OF THE SAME PROTEIN REMARK 900 RELATED ID: 30678 RELATED DB: BMRB REMARK 900 STRUCTURE OF THE HIV-1 GP41 TRANSMEMBRANE DOMAIN AND CYTOPLASMIC REMARK 900 TAIL (LLP2) DBREF1 6UJU A 677 788 UNP A0A386YSI0_9HIV1 DBREF2 6UJU A A0A386YSI0 682 793 DBREF1 6UJU B 677 788 UNP A0A386YSI0_9HIV1 DBREF2 6UJU B A0A386YSI0 682 793 DBREF1 6UJU C 677 788 UNP A0A386YSI0_9HIV1 DBREF2 6UJU C A0A386YSI0 682 793 SEQADV 6UJU ARG A 683 UNP A0A386YSI LYS 688 CONFLICT SEQADV 6UJU ILE A 687 UNP A0A386YSI MET 692 CONFLICT SEQADV 6UJU SER A 691 UNP A0A386YSI GLY 696 CONFLICT SEQADV 6UJU ILE A 693 UNP A0A386YSI VAL 698 CONFLICT SEQADV 6UJU LEU A 704 UNP A0A386YSI ILE 709 CONFLICT SEQADV 6UJU SER A 764 UNP A0A386YSI CYS 769 ENGINEERED MUTATION SEQADV 6UJU ARG B 683 UNP A0A386YSI LYS 688 CONFLICT SEQADV 6UJU ILE B 687 UNP A0A386YSI MET 692 CONFLICT SEQADV 6UJU SER B 691 UNP A0A386YSI GLY 696 CONFLICT SEQADV 6UJU ILE B 693 UNP A0A386YSI VAL 698 CONFLICT SEQADV 6UJU LEU B 704 UNP A0A386YSI ILE 709 CONFLICT SEQADV 6UJU SER B 764 UNP A0A386YSI CYS 769 ENGINEERED MUTATION SEQADV 6UJU ARG C 683 UNP A0A386YSI LYS 688 CONFLICT SEQADV 6UJU ILE C 687 UNP A0A386YSI MET 692 CONFLICT SEQADV 6UJU SER C 691 UNP A0A386YSI GLY 696 CONFLICT SEQADV 6UJU ILE C 693 UNP A0A386YSI VAL 698 CONFLICT SEQADV 6UJU LEU C 704 UNP A0A386YSI ILE 709 CONFLICT SEQADV 6UJU SER C 764 UNP A0A386YSI CYS 769 ENGINEERED MUTATION SEQRES 1 A 112 ASN TRP LEU TRP TYR ILE ARG ILE PHE ILE ILE ILE VAL SEQRES 2 A 112 GLY SER LEU ILE GLY LEU ARG ILE VAL PHE ALA VAL LEU SEQRES 3 A 112 SER LEU VAL ASN ARG VAL ARG GLN GLY TYR SER PRO LEU SEQRES 4 A 112 SER PHE GLN THR HIS LEU PRO THR PRO ARG GLY PRO ASP SEQRES 5 A 112 ARG PRO GLU GLY ILE GLU GLU GLU GLY GLY GLU ARG ASP SEQRES 6 A 112 ARG ASP ARG SER ILE ARG LEU VAL ASN GLY SER LEU ALA SEQRES 7 A 112 LEU ILE TRP ASP ASP LEU ARG SER LEU SER LEU PHE SER SEQRES 8 A 112 TYR HIS ARG LEU ARG ASP LEU LEU LEU ILE VAL THR ARG SEQRES 9 A 112 ILE VAL GLU LEU LEU GLY ARG ARG SEQRES 1 B 112 ASN TRP LEU TRP TYR ILE ARG ILE PHE ILE ILE ILE VAL SEQRES 2 B 112 GLY SER LEU ILE GLY LEU ARG ILE VAL PHE ALA VAL LEU SEQRES 3 B 112 SER LEU VAL ASN ARG VAL ARG GLN GLY TYR SER PRO LEU SEQRES 4 B 112 SER PHE GLN THR HIS LEU PRO THR PRO ARG GLY PRO ASP SEQRES 5 B 112 ARG PRO GLU GLY ILE GLU GLU GLU GLY GLY GLU ARG ASP SEQRES 6 B 112 ARG ASP ARG SER ILE ARG LEU VAL ASN GLY SER LEU ALA SEQRES 7 B 112 LEU ILE TRP ASP ASP LEU ARG SER LEU SER LEU PHE SER SEQRES 8 B 112 TYR HIS ARG LEU ARG ASP LEU LEU LEU ILE VAL THR ARG SEQRES 9 B 112 ILE VAL GLU LEU LEU GLY ARG ARG SEQRES 1 C 112 ASN TRP LEU TRP TYR ILE ARG ILE PHE ILE ILE ILE VAL SEQRES 2 C 112 GLY SER LEU ILE GLY LEU ARG ILE VAL PHE ALA VAL LEU SEQRES 3 C 112 SER LEU VAL ASN ARG VAL ARG GLN GLY TYR SER PRO LEU SEQRES 4 C 112 SER PHE GLN THR HIS LEU PRO THR PRO ARG GLY PRO ASP SEQRES 5 C 112 ARG PRO GLU GLY ILE GLU GLU GLU GLY GLY GLU ARG ASP SEQRES 6 C 112 ARG ASP ARG SER ILE ARG LEU VAL ASN GLY SER LEU ALA SEQRES 7 C 112 LEU ILE TRP ASP ASP LEU ARG SER LEU SER LEU PHE SER SEQRES 8 C 112 TYR HIS ARG LEU ARG ASP LEU LEU LEU ILE VAL THR ARG SEQRES 9 C 112 ILE VAL GLU LEU LEU GLY ARG ARG HELIX 1 AA1 ASN A 677 GLN A 710 1 34 HELIX 2 AA2 ASP A 741 ILE A 746 1 6 HELIX 3 AA3 ARG A 747 SER A 764 1 18 HELIX 4 AA4 ARG A 770 ARG A 787 1 18 HELIX 5 AA5 TRP B 678 ARG B 696 1 19 HELIX 6 AA6 ILE B 697 GLN B 710 1 14 HELIX 7 AA7 ASP B 741 ILE B 746 1 6 HELIX 8 AA8 ILE B 746 LEU B 765 1 20 HELIX 9 AA9 SER B 767 ARG B 787 1 21 HELIX 10 AB1 TRP C 678 ILE C 697 1 20 HELIX 11 AB2 ILE C 697 GLN C 710 1 14 HELIX 12 AB3 ARG C 740 ARG C 747 1 8 HELIX 13 AB4 ARG C 747 SER C 764 1 18 HELIX 14 AB5 ARG C 770 GLY C 786 1 17 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1